Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17101405 | 0.88 | MAPT (0.60) | MAPTSMN1; SMN2HTTPOLBKMT2A | |
| SCHEMBL17101044 | 0.84 | POLB (0.45) | MAPTSMN1; SMN2HTTPOLBKMT2A | |
| SCHEMBL17101100 | 0.84 | ALDH1A1 (0.47) | MAPTSMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL17101036 | 0.83 | PTGS1 (0.42) | SMN1; SMN2HTTKMT2AMEN1CYP3A4 | |
| SCHEMBL17101083 | 0.82 | ABL1 (0.48) | HTTPOLBALDH1A1LMNA | |
| SCHEMBL17101086 | 0.78 | WNT3A (0.50) | — | |
| SCHEMBL17101124 | 0.76 | ALDH1A1 (0.50) | MAPTSMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL20855699 | 0.74 | MEN1 (0.60) | MAPTSMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL17101125 | 0.73 | ALDH1A1 (0.47) | MAPTSMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL16097836 | 0.73 | KCNQ3 (0.49) | MAPTSMN1; SMN2POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114070-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170114070-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170107212-A1 | NOVEL COMPOUNDS | Bayer Pharma AG (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107212-A1 | NOVEL COMPOUNDS | Bayer Pharma AG (DE) | 2017-04-20 | — | — | US | disclosed |
| EP-3119787-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119759-A1 | NOVEL COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140195-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140196-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140195-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140196-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114070-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | WNT1, WNT3A, CTNNB1 | MAPT 2002/4885SMN1; SMN2 3484/4885HTT 2314/4885 |
| US-20170107212-A1 | NOVEL COMPOUNDS | WNT1, CTNNB1, WNT3A | MAPT 2042/4885SMN1; SMN2 2586/4885HTT 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.